Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Canon Inc.

www.canon.com

Latest From Canon Inc.

Market Intel: Breast Imaging Market Driven By AI, Technological Innovation

The global market for breast cancer imaging and biopsy technologies is expected to reach $5.8bn by 2022, a CAGR of 5.9%, driven by innovation technologies and machine-learning tools that serve as "second readers" to help radiologists triage images and find cancers. Many radiologists believe that mammography will remain the most widely used screening tool, but that digital breast tomosynthesis will ultimately become the gold standard. Here's a close look at the overall breast imaging and biopsy market, highlighting different modalities and key players, and offering the real-world use perspective from three radiologists at Kaiser Permanente, San Diego.

Commercial Market Intelligence

Philips Hails 'New Day' For Digital Diagnosis And AI As UK Govt Supports Five Specialist Centers

Several major global health-care diagnostics groups have won bids to spearhead five new UK centers of excellence for digital pathology and imaging, including radiology and using AI medical advances. A key aim of the initiative, provided for under the UK Life Sciences Industrial Strategy, is to create a brand new commercial sector around the development of AI for diagnostics, says Neil Mesher, CEO of Philips UK and Ireland, which has a role in two of the centers.

United Kingdom Digital Health

Device/Diagnostics Quarterly Deal Statistics, Q4 2016

Medtech companies raised $2.4 billion in the fourth quarter, the second-strongest of the year; Q4 device M&A deals totaled $9 billion in value, led by Allergan's $2.9 billion buy of Acelity's LifeCell division. Diagnostics financings finished out the year at $721 million, an increase over the previous quarter and 2016's second-highest quarter, but diagnostics M&A activity was the lowest of the year at $87 million, with only two completed acquisitions.

Deals Medical Device

Deals In Depth: March 2016

Sanofi signed a $2bn deal with DiCE Molecules to develop small molecules against targets previously addressed by biologics; Toshiba sold its diagnostics and medical imaging division to Canon for $6bn. Debt offerings dominated biopharma and device financings.

BioPharmaceutical Medical Device
See All
Advertisement
Advertisement
UsernamePublicRestriction

Register